Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is mainly expressed in the liver but can also be found in the intestine and kidneys. PCSK9 promotes the degradation of low density lipoprotein receptors (LDLR) by reducing their recycling and targeting the receptors for...
Main Authors: | Constantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, Frank Garcia, Peter D Montan, Eliscer Guzman |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2017-11-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | http://www.drugsincontext.com/lipid-lowering-interventions-targeting-proprotein-convertase-subtilisinkexin-type-9-pcsk9-an-emerging-chapter-in-lipid-lowering-therapy/ |
Similar Items
-
THE INVOLVEMENT PROPROTEIN CONVERTASE SUBTILISIN/KEXIN OF TYPE 9 IN THE PATHOGENESIS OF ATHEROSCLEROSIS (LITERATURE REVIEW)
by: A. M. Chaulin
Published: (2020-03-01) -
The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
by: Patchareeya Amput, et al.
Published: (2019-01-01) -
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
by: Holly E. Careskey, et al.
Published: (2008-02-01) -
Targeting pro-protein convertase subtilisin kexin-9 as a novel therapy of hypercholesterolemia
by: Bambang Dwiputra, et al.
Published: (2017-08-01) -
Proprotein convertase subtilisin/kexin type 9 in human disease
by: Awan, Zuhier
Published: (2011)